Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial.

The article presents a study which aims to improve the safety of durable polymer drug-eluting stents by avoiding the persistent inflammatory stimulus of durable polymers. The study uses multicentre and non-inferiority trial which was done in ten centres in Europe and applied broad inclusion criteria. Results show that patients with lesions were randomly allocated to receive biodegradable polymer biolimus-eluting stents (BES) or durable polymer sirolimus-eluting stent (SES).